摘要
放射性核素可以标记于具有特异性结合能力的生物分子上,通过与肿瘤的特异性靶点结合,核素发出的α或β等粒子将特异性地照射肿瘤并产生电离辐射效应,导致照射范围内的细胞衰老和死亡,达到肿瘤治疗结果,且这种方式对周围正常组织影响小。镥-^(177)(^(177)Lu)能够发射γ射线,用于CT显像;还可发射β射线,用于肿瘤治疗。因此^(177)Lu是目前可用于诊疗一体化的放射性医用核素之一。该综述结合目前已发表的研究,简要介绍^(177)Lu在几种实体肿瘤中的临床应用。
Radionuclides can be labeled on biomolecules with specific binding ability.By binding with specific targets of tumors,particles such asαorβemitted by the radionuclides will specifically irradiate tumors and produce ionizing radiation effects,resulting in cell senescence and death within the irradiation range,achieving tumor treatment results,and this way has little impact on surrounding normal tissues.Lutetium-^(177)(^(177)Lu)can emitγrays for CT imaging,and can also emitβrays for tumor treatment,so ^(177)Lu is now one of the radionuclides that can be used for integrated diagnosis and treatment.This review summarizes the clinical application of ^(177)Lu in several solid tumors,in conjunction with currently published research.
作者
牛婷婷
杜小波
NIU Tingting;DU Xiaobo(Department of Clinical Medicine,North Sichuan Medical College,Nanchong,Sichuan 637000,P.R.China;Department of Oncology,Mianyang Central Hospital,Mianyang,Sichuan 621000,P.R.China)
出处
《华西医学》
CAS
2023年第7期1100-1106,共7页
West China Medical Journal
基金
国家卫生健康委核技术医学转化重点实验室基金(2021HYX001,2021HYX015)。
